494 related articles for article (PubMed ID: 26033501)
21. DICER1 hot-spot mutations in ovarian gynandroblastoma.
Wang Y; Karnezis AN; Magrill J; Tessier-Cloutier B; Lum A; Senz J; Gilks CB; McCluggage WG; Huntsman DG; Kommoss F
Histopathology; 2018 Aug; 73(2):306-313. PubMed ID: 29660837
[TBL] [Abstract][Full Text] [Related]
22. Detection of the DICER1 hotspot mutation alongside immunohistochemical analysis may provide a better diagnostic measure for ovarian Sertoli-Leydig cell tumors.
Zhang X; Shen D; Wang Y
Pathol Res Pract; 2018 Sep; 214(9):1370-1375. PubMed ID: 30072170
[TBL] [Abstract][Full Text] [Related]
23. Practical roles for molecular diagnostic testing in ovarian adult granulosa cell tumour, Sertoli-Leydig cell tumour, microcystic stromal tumour and their mimics.
Rabban JT; Karnezis AN; Devine WP
Histopathology; 2020 Jan; 76(1):11-24. PubMed ID: 31846522
[TBL] [Abstract][Full Text] [Related]
24. Update on Ovarian Sex Cord-Stromal Tumors.
Ordulu Z
Clin Lab Med; 2023 Jun; 43(2):245-274. PubMed ID: 37169445
[TBL] [Abstract][Full Text] [Related]
25. Update on Ovarian Sex Cord-Stromal Tumors.
Ordulu Z
Surg Pathol Clin; 2022 Jun; 15(2):235-258. PubMed ID: 35715160
[TBL] [Abstract][Full Text] [Related]
26. Gynecologic Manifestations of the DICER1 Syndrome.
Stewart CJ; Charles A; Foulkes WD
Surg Pathol Clin; 2016 Jun; 9(2):227-41. PubMed ID: 27241106
[TBL] [Abstract][Full Text] [Related]
27. FOXL2 Mutation Status in Sex Cord-stromal Tumors Cannot be Predicted by Morphology.
Wessman S; Fuentes BB; Severin-Karlsson J; Westbom-Fremer S; Nistér M; Kokaraki G; Petta TB; Haglund F; Carlson JW
Int J Gynecol Pathol; 2024 Jan; 43(1):78-89. PubMed ID: 37255476
[TBL] [Abstract][Full Text] [Related]
28. Pediatric Sertoli-Leydig Cell Tumors of the Ovary: An Integrated Study of Clinicopathological Features, Pan-cancer-Targeted Next-generation Sequencing and Chromosomal Microarray Analysis From a Single Institution.
Yang B; Chour W; Salazar CG; Zamiara P; Schmidt RJ; Raca G; Shillingford N; Zhou S; Warren M; Parham DM; Pawel B; Wang LL
Am J Surg Pathol; 2024 Feb; 48(2):194-203. PubMed ID: 37946548
[TBL] [Abstract][Full Text] [Related]
29. An immunohistochemical and molecular analysis of problematic and unclassified ovarian sex cord-stromal tumors.
Stewart CJ; Alexiadis M; Crook ML; Fuller PJ
Hum Pathol; 2013 Dec; 44(12):2774-81. PubMed ID: 24134930
[TBL] [Abstract][Full Text] [Related]
30. Lessons from genomic profiling: towards a molecular-based classification of ovarian Sertoli-Leydig cell tumour.
Kommoss FKF
Histopathology; 2024 Mar; 84(4):712-714. PubMed ID: 38114269
[TBL] [Abstract][Full Text] [Related]
31. Lack of mutation of DICER1 and FOXL2 genes in microcystic stromal tumor of the ovary.
Meurgey A; Descotes F; Mery-Lamarche E; Devouassoux-Shisheboran M
Virchows Arch; 2017 Feb; 470(2):225-229. PubMed ID: 27830327
[TBL] [Abstract][Full Text] [Related]
32. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary.
Al-Agha OM; Huwait HF; Chow C; Yang W; Senz J; Kalloger SE; Huntsman DG; Young RH; Gilks CB
Am J Surg Pathol; 2011 Apr; 35(4):484-94. PubMed ID: 21378549
[TBL] [Abstract][Full Text] [Related]
33. Testicular Neoplasms With Sex Cord and Stromal Components Harbor a Recurrent Pattern of Chromosomal Gains.
Acosta AM; Sholl LM; Maclean F; Kao CS; Ulbright TM
Mod Pathol; 2024 Jan; 37(1):100368. PubMed ID: 37871653
[TBL] [Abstract][Full Text] [Related]
34. Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network.
Maillet D; Goulvent T; Rimokh R; Vacher-Lavenu MC; Pautier P; Alexandre J; Pujade-Laurraine E; Devouassoux-Shisheboran M; Treilleux I; Ray-Coquard I; Savina A
Gynecol Oncol; 2014 Jan; 132(1):181-7. PubMed ID: 24157616
[TBL] [Abstract][Full Text] [Related]
35. [Sex cord-stromal tumors of the ovary : Current aspects with a focus on granulosa cell tumors, Sertoli-Leydig cell tumors, and gynandroblastomas].
Kommoss F; Lehr HA
Pathologe; 2019 Feb; 40(1):61-72. PubMed ID: 30659330
[TBL] [Abstract][Full Text] [Related]
36. DICER1 -Altered Extraovarian Moderately Differentiated Sertoli-Leydig Cell Tumor: Report of a Rare Case.
Lau JCC; McCluggage WG; Yuen LYP; Shing MMK; Chan GCF; Yam FSD; Leung MWY; Ng WF; Liu APY
Int J Gynecol Pathol; 2023 Jul; 42(4):421-425. PubMed ID: 36044308
[TBL] [Abstract][Full Text] [Related]
37. Clinical Characteristics and Mutation Analyses of Ovarian Sertoli-Leydig Cell Tumors.
Yuan Z; Huo X; Jiang D; Yu M; Cao D; Wu H; Shen K; Yang J; Zhang Y; Zhou H; Wang Y
Oncologist; 2020 Sep; 25(9):e1396-e1405. PubMed ID: 32557933
[TBL] [Abstract][Full Text] [Related]
38. Somatic tumour testing establishes that bilateral DICER1-associated ovarian Sertoli-Leydig cell tumours represent independent primary neoplasms.
McCluggage WG; Chong AL; de Kock L; Foulkes WD
Histopathology; 2020 Aug; 77(2):223-230. PubMed ID: 32333409
[TBL] [Abstract][Full Text] [Related]
39. The oncogenic roles of DICER1 RNase IIIb domain mutations in ovarian Sertoli-Leydig cell tumors.
Wang Y; Chen J; Yang W; Mo F; Senz J; Yap D; Anglesio MS; Gilks B; Morin GB; Huntsman DG
Neoplasia; 2015 Aug; 17(8):650-60. PubMed ID: 26408257
[TBL] [Abstract][Full Text] [Related]
40. DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors.
Rio Frio T; Bahubeshi A; Kanellopoulou C; Hamel N; Niedziela M; Sabbaghian N; Pouchet C; Gilbert L; O'Brien PK; Serfas K; Broderick P; Houlston RS; Lesueur F; Bonora E; Muljo S; Schimke RN; Bouron-Dal Soglio D; Arseneau J; Schultz KA; Priest JR; Nguyen VH; Harach HR; Livingston DM; Foulkes WD; Tischkowitz M
JAMA; 2011 Jan; 305(1):68-77. PubMed ID: 21205968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
